Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
2219907
Reference Type
Journal Article
Title
Development of Transdermal Ondansetron Hydrochloride for the Treatment of Chemotherapy-Induced Nausea and Vomiting
Author(s)
Rajabalaya, R; Chen, DS; David, SRN
Year
2013
Is Peer Reviewed?
1
Journal
Tropical Journal of Pharmaceutical Research
ISSN:
1596-5996
Volume
12
Issue
3
Page Numbers
279-285
DOI
10.4314/tjpr.v12i3.1
Web of Science Id
WOS:000320760400001
Abstract
Purpose: To to develop and evaluate matrix-type ondansetron hydrochloride (OS) transdermal patch for the treatment of chemotherapy-induced nausea and vomiting.
Methods: Transdermal patches were prepared by solvent casting method using ethyl cellulose and polyvinyl pyrrolidone as matrix materials, and dibutyl phthalate and dibutyl sebacate as plasticizers. The formulations were evaluated for patch thickness, tensile strength, moisture content, water absorption capacity and drug content. In vitro drug release and permeation of the patches were determined using a Franz diffusion cell.
Results: the tensile strength of all the formulations was in the range from 6.09 to 9.85 Mpa indicating that the [patches were strong. Maximum drug release in 8 h for dibutyl phthalate DBP and dibutyl sebacate DBS patches was 38.9 (DB6) and 53.4 % (DS3), respectively, which are significantly (p < 0.01) higher than the lowest values of 17.8 (for DB1) and 35.0 % for (DS5), respectively. Drug release rate was 1.89 and 3.93 mu g/h/cm(2), respectively with DS2 and DB2 showing the highest permeation rate of 5.39 mu g/h/cm(2). Patches containing DBP followed Higuchi release model while patches formulated with DBS followed first order release kinetics.
Conclusion: Ondansetron matrix-type transdermal patches formulated with suitable amounts of chemical enhancers for better patient compliance are feasible.
Keywords
Ondansetron hydrochloride; Chemical enhancers; Plasticizers; Dibutyl phthalate; Dibutyl sebacate; Permeation; Patch
Tags
IRIS
•
Dibutyl Phthalate (DBP)
Database Searches
Web of Science
LitSearch June 2013 – Jan 2014
Web of Science
Excluded: No Primary Data on Health Effects
Not chemical specific
OPPT
•
Dibutyl sebacate
Literature Search
Human Health
WOS (private)
Fate
WOS (private)
Environmental Hazard
WOS (private)
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity